#14805

CIP2A (D1M3H) Rabbit mAb



Orders:	877-616-CELL (2355) orders@cellsignal.com			
Support:	877-678-TECH (8324)			
Web:	info@cellsignal.com cellsignal.com			

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 90	Source/Isotype: Rabbit IgG	UniProt ID: #Q8TCG1	Entrez-Gene Id: 57650		
Product Usage Information	2	Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:100			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Ser	nsitivity	CIP2A (D1M3H) Rabbit mAb recognizes endogenous levels of total CIP2A protein.						
Source / Purifi	e / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding val342 of human CIP2A protein.					prresponding to		
Background		Protein phosphatase 2A (PP2A) is a trimeric protein phosphatase and tumor suppressor that regulates the phosphorylation status of a wide variety of phosphoproteins. PP2A targets include many that play a role in the maintenance and progression of cancer (1). The cancerous inhibitor of protein phosphatase 2A (CIP2A) is a single pass membrane protein that binds the PP2A catalytic subunit to inhibit PP2A phosphatase activity (2). CIP2A is normally expressed at low levels in normal cells and tissues, but is elevated in human malignancies where it is thought to be oncogenic. Research studies demonstrate aberrant CIP2A expression in multiple tumor types, including those derived from the head and neck, liver, colon, lung, osteosarcoma, pancreatic, breast, and myeloid cancers (reviewed in 3). This evidence suggests that CIP2A interacts with many proteins that may play a role in cancer maintenance and progression (3). Additional studies indicate that CIP2A inhibits PP2A-mediated dephosphorylation of the proto-oncogene Myc at Ser64, which stabilizes and prevents proteolytic degradation of the Myc transcription factor (4).						
Background R	eferences	1. Westermarck, J. and Hahn, W.C. (2008) <i>Trends Mol Med</i> 14, 152-60. 2. Junttila, M.R. et al. (2007) <i>Cell</i> 130, 51-62. 3. De, P. et al. (2014) <i>Oncotarget</i> 5, 4581-602. 4. Junttila, M.R. and Westermarck, J. (2008) <i>Cell Cycle</i> 7, 592-6.						
Species Reacti	vity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).						
Western Blot B	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ley	W: Western Blotting IP: Immunoprecipitation						
Cross-Reactivi	ty Key	H: Human						
Trademarks aı	nd Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks f more information.							
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.						
		Products are labeled wi approved, cleared, or lio						

purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST product or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.